Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients
Launched by BENI-SUEF UNIVERSITY · Sep 12, 2022
Trial Information
Current as of October 16, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether a combination of two medications, allopurinol and trimetazidine, can help prevent acute kidney injury (AKI) in patients undergoing a procedure called percutaneous coronary intervention (PCI). AKI is a common complication that can occur after using a special dye (contrast) during these procedures, and it can lead to longer hospital stays and higher medical costs. The trial aims to find out if using both medications together is more effective than using just one to protect the kidneys in patients with different risk levels.
To be eligible for this trial, participants need to be adults aged between 18 and 80 years, with normal kidney function (glomerular filtration rate greater than 60 mL/min) and willing to undergo PCI. However, those with certain conditions, such as existing kidney injury or specific allergies, cannot participate. If you join the trial, you'll receive either the combination of the two medications or just one of them, and the medical team will monitor your kidney function closely during and after the procedure. This study is important because it could help improve patient care and outcomes for those at risk of kidney complications following PCI.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients willing to undergo PCI with low, moderate or high risk of CIN based on Mehran risk score (4)
- • Age 18 - 80 years
- • Patients with GFR \> 60 ml/min
- Exclusion Criteria:
- • Age \<18 or \> 80 years
- • Acute kidney injury
- • Renal insufficiency (eGFR \< 60 mL/min)
- • Gout (serum uric \> 10 mg/dL)
- • History of allopurinol intake.
- • Hepatic failure.
- • Pregnancy or lactation,
- • History of allergy to contrast agents, allopurinol or trimetazidine
- • Any nephrotoxic drug intake within 48 hrs. before the procedure
- • Pulmonary edema, cardiogenic shock and mechanical ventilation.
About Beni Suef University
Beni-Suef University is a prominent academic institution in Egypt dedicated to advancing medical research and clinical trials aimed at improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university fosters a multidisciplinary approach to research, engaging faculty, students, and healthcare professionals in the pursuit of scientific knowledge. The institution is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring that all clinical trials conducted under its auspices are designed to enhance patient care and contribute to the global body of medical research. Through its initiatives, Beni-Suef University aims to translate research findings into practical applications that benefit communities locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Banī Suwayf, Beni Suef, Egypt
Patients applied
Trial Officials
Mohamed Emam abd Elmobdy, Professor
Study Chair
clinical pharmacy Beni-Suef university
Naglaa Samir Bazan, Assoc. Prof
Principal Investigator
clinical pharmacy critical care medicine, Cairo university
Hatem Hossam Mowafi, Doctor
Principal Investigator
Lecturer critical care medicine , Cairo university
Hadeer Safwat Hassan Zaki, Doctor
Study Director
Clinical Pharmacy, Beni-Suef University
Nourhan Osama Ali Moselhy, BSc
Principal Investigator
Egyptian Drug Authority
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials